Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial

非布索坦 医学 高尿酸血症 安慰剂 肾功能 内科学 肾脏疾病 尿酸 蛋白尿 无症状的 随机对照试验 泌尿科 肌酐 胃肠病学 病理 替代医学
作者
Kenjiro Kimura,Tatsuo Hosoya,Shunya Uchida,Masaaki Inaba,Hirofumi Makino,Shoichi Maruyama,Sadayoshi Ito,Tetsuya Yamamoto,Yasuhiko Tomino,Iwao Ohno,Yugo Shibagaki,Satoshi Iimuro,Naohiko Imai,Masanari Kuwabara,Hiroshi Hayakawa,Hiroshi Ohtsu,Yasuo Ohashi,Kenjiro Kimura,Tatsuo Hosoya,Sadayoshi Ito
出处
期刊:American Journal of Kidney Diseases [Elsevier BV]
卷期号:72 (6): 798-810 被引量:313
标识
DOI:10.1053/j.ajkd.2018.06.028
摘要

Rationale & ObjectiveEpidemiologic and clinical studies have suggested that urate-lowering therapy may slow the progression of chronic kidney disease (CKD). However, definitive evidence is lacking.Study DesignRandomized, double-blind, placebo-controlled trial.Setting & Participants467 patients with stage 3 CKD and asymptomatic hyperuricemia at 55 medical institutions in Japan.InterventionParticipants were randomly assigned in a 1:1 ratio to receive febuxostat or placebo for 108 weeks.OutcomesThe primary end point was the slope (in mL/min/1.73 m2 per year) of estimated glomerular filtration rate (eGFR). Secondary end points included changes in eGFRs and serum uric acid levels at 24, 48, 72, and 108 weeks of follow-up and the event of doubling of serum creatinine level or initiation of dialysis therapy.ResultsOf 443 patients who were randomly assigned, 219 and 222 assigned to febuxostat and placebo, respectively, were included in the analysis. There was no significant difference in mean eGFR slope between the febuxostat (0.23 ± 5.26 mL/min/1.73 m2 per year) and placebo (−0.47 ± 4.48 mL/min/1.73 m2 per year) groups (difference, 0.70; 95% CI, −0.21 to 1.62; P = 0.1). Subgroup analysis demonstrated a significant benefit from febuxostat in patients without proteinuria (P = 0.005) and for whom serum creatinine concentration was lower than the median (P = 0.009). The incidence of gouty arthritis was significantly lower (P = 0.007) in the febuxostat group (0.91%) than in the placebo group (5.86%). Adverse events specific to febuxostat were not observed.LimitationsGFR was estimated rather than measured, and patients with stages 4 and 5 CKD were excluded.ConclusionsCompared to placebo, febuxostat did not mitigate the decline in kidney function among patients with stage 3 CKD and asymptomatic hyperuricemia.FundingFunded by Teijin Pharma Limited.Trial RegistrationRegistered at the UMIN (University Hospital Medical Information Network) Clinical Trials Registry with study number UMIN000008343. Epidemiologic and clinical studies have suggested that urate-lowering therapy may slow the progression of chronic kidney disease (CKD). However, definitive evidence is lacking. Randomized, double-blind, placebo-controlled trial. 467 patients with stage 3 CKD and asymptomatic hyperuricemia at 55 medical institutions in Japan. Participants were randomly assigned in a 1:1 ratio to receive febuxostat or placebo for 108 weeks. The primary end point was the slope (in mL/min/1.73 m2 per year) of estimated glomerular filtration rate (eGFR). Secondary end points included changes in eGFRs and serum uric acid levels at 24, 48, 72, and 108 weeks of follow-up and the event of doubling of serum creatinine level or initiation of dialysis therapy. Of 443 patients who were randomly assigned, 219 and 222 assigned to febuxostat and placebo, respectively, were included in the analysis. There was no significant difference in mean eGFR slope between the febuxostat (0.23 ± 5.26 mL/min/1.73 m2 per year) and placebo (−0.47 ± 4.48 mL/min/1.73 m2 per year) groups (difference, 0.70; 95% CI, −0.21 to 1.62; P = 0.1). Subgroup analysis demonstrated a significant benefit from febuxostat in patients without proteinuria (P = 0.005) and for whom serum creatinine concentration was lower than the median (P = 0.009). The incidence of gouty arthritis was significantly lower (P = 0.007) in the febuxostat group (0.91%) than in the placebo group (5.86%). Adverse events specific to febuxostat were not observed. GFR was estimated rather than measured, and patients with stages 4 and 5 CKD were excluded. Compared to placebo, febuxostat did not mitigate the decline in kidney function among patients with stage 3 CKD and asymptomatic hyperuricemia.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
末末完成签到 ,获得积分10
8秒前
无为完成签到 ,获得积分10
9秒前
白嫖论文完成签到 ,获得积分10
11秒前
上官若男应助忧伤的步美采纳,获得10
14秒前
科研通AI2S应助科研通管家采纳,获得10
14秒前
17秒前
从心随缘完成签到 ,获得积分10
18秒前
花花发布了新的文献求助10
20秒前
牛奶面包完成签到 ,获得积分10
21秒前
22秒前
岁月如歌完成签到 ,获得积分0
22秒前
25秒前
Li完成签到,获得积分10
27秒前
张琨完成签到 ,获得积分10
27秒前
27秒前
sunnyqqz完成签到,获得积分10
30秒前
热情的乘风完成签到,获得积分20
30秒前
32秒前
霍凡白完成签到,获得积分10
33秒前
34秒前
Feng发布了新的文献求助20
35秒前
怕孤单的若颜完成签到 ,获得积分10
37秒前
38秒前
ruochenzu发布了新的文献求助10
41秒前
zhongu发布了新的文献求助10
45秒前
阳光彩虹小白马完成签到 ,获得积分10
45秒前
Feng完成签到,获得积分10
47秒前
花花完成签到,获得积分10
49秒前
52秒前
量子星尘发布了新的文献求助10
54秒前
杨一完成签到 ,获得积分10
57秒前
猫猫头完成签到 ,获得积分10
58秒前
1分钟前
1分钟前
忒寒碜完成签到,获得积分10
1分钟前
1分钟前
XU博士完成签到,获得积分10
1分钟前
哭泣青烟完成签到 ,获得积分10
1分钟前
roundtree完成签到 ,获得积分0
1分钟前
等待谷南完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038039
求助须知:如何正确求助?哪些是违规求助? 3575756
关于积分的说明 11373782
捐赠科研通 3305574
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022